Could humble tulips harbour a secret killer? John believes infected compost caused his wife's death
John Pibworth, 77, a retired flooring contractor from Shropshire, believes infected compost was responsible for infecting his late wife, Ann, with aspergillosis. (Source: the Mail online | Health)
Source: the Mail online | Health - April 29, 2019 Category: Consumer Health News Source Type: news
Researchers' breakthrough in tackling challenge of antifungal resistance
(Swansea University) Ground-breaking work by university experts in Tennessee, Texas and Swansea is helping develop a better understanding of the growing threat posed by antifungal drug resistance. Invasive aspergillosis is a devastating disease caused by breathing in small airborne spores of the fungus Aspergillus fumigatus and it is a condition where drug resistance has been encountered. They have just released a paper revealing how they have been able to identify a previously uncharacterized genetic mutation in clinical isolates that leads to resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2019 Category: International Medicine & Public Health Source Type: news
9th Advances Against Aspergillosis and Mucormycosis
Date: Monday, March 4, 2019Year: 2020Location: Lugano, SwitzerlandContent-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 4, 2019 Category: Respiratory Medicine Authors: helenfindon Source Type: news
Diagnosis and treatment of chronic pulmonary aspergillosis
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 26, 2019 Category: Respiratory Medicine Authors: helenfindon Source Type: news
Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy
Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma.
The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 7, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news
Clinical Fellow - Infectious Diseases and Aspergillosis
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 21, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Journal for Antimicrobial Chemotherapy-Medical Mycology Joint Issue
Aspergillosis continues to be a frequent cause of opportunistic infection and mortality among patients with suppressed immunity and those with airway diseases. This virtual issue is a joint endeavour between the Journal of Antimicrobial Chemotherapy and Medical Mycology to highlight the diagnosis and the clinical aspects of the management of chronic aspergillosis as well as the relatively new phenomenon of emergent azole resistance.ISHAM hope the reader will find the collection useful in gaining new insights into aspergillosis from a laboratory and clinical perspective. Wednesday, December 19, 2018 - 18:19Updates (Source...
Source: The Aspergillus Website - updates - December 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Isavuconazole good value for money in invasive aspergillosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news
Allergic bronchopulmonary aspergillosis complicating COPD is associated with a higher exacerbation rate and a distinct pattern on chest CT scan compared to COPD
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
IgE immunadsorption in allergic bronchopulmonary aspergillosis: A pilot study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Treatment outcome in patients with chronic pulmonary aspergillosis by azole-resistant aspergillus fumigatus
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 23, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
An Optimized, Large Scale Generation and Validation of Aspergillus-Specific T Lymphocytes for the Management of Invasive Aspergillosis in Immunocompromised Patients
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
A Ball of Fun: Allergic Bronchopulmonary Aspergillosis Presenting as a Pneumothorax
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
